Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study [CNBC]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: CNBC
Shelby Knowles | Bloomberg | Getty Images Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results ?in patients with the skin disease and obesity in a late-stage ?study, compared ?to Taltz alone. The ?drugs showed greater improvement in skin symptoms and weight loss in the study of 274 patients. ?About ?27.1% of patients who had received Taltz ?and Zepbound reached complete skin clearance and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone ?at 36 weeks, meeting the main goal. Psoriasis is a chronic condition that causes itchy, scaly patches ?on the skin. Nearly all trial participants had psoriasis affecting sensitive areas such as the face, scalp or genitals, which are typically hard to ?treat, Lilly said. In the U.S., about 61% of people ?with psoriasis also have obesity or ?are overweight with at least one weight-related co-morbidity, Lilly said. Adverse events during the study
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects [Seeking Alpha]Seeking Alpha
- Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Daiwa Securities Group Inc. from $1,230.00 to $1,250.00. They now have a "buy" rating on the stock.MarketBeat
- Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPR Newswire
- Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and CompanyBusiness Wire
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website